DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs

Eric Raymond, Jean Charles Soria, Elzbieta Izbicka, Francois Boussin, Laurence Hurley, Daniel D. Von Hoff

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Telomeres and telomerase have been subjects to a tremendous attention from scientists and oncologists during the past 5 years. This interest has been motivated by the potential of telomerase as a tumor marker for the diagnosis and the prognosis of cancer. The possible use of telomerase or telomeres as new targets for anticancer drugs also triggered investigations. The expression of telomerase was found in overall 85% of cancers. Telomerase is early expressed during oncogenesis with a gradient indicating that a high level of telomerase expression could be associated with a bad prognosis. Therefore, drugs targeting telomerase and telomeres might be useful in many human tumors with little restrictions regarding the tumor type or on the stage of the disease. Moreover, since telomerase is not or slightly expressed in normal cells, it has been postulated that drugs targeting telomerase would induce low toxicity. The race for the discovery of telomerase inhibitors has started while the identification of the components controlling telomerase, telomeres, cell survival, senescence, and apoptosis was still in progress. The recent identification of components regulating telomere length and telomerase expression (TRF1, TRF2, and tankyrase) opened a variety of new opportunities to control telomerase/telomere interactions. Meanwhile, a proof of principle was provided that changing telomere interactions with telomere binding proteins by chemical or biological means can induce cancer cell death. Interestingly, recent data challenge the old paradigm which suggested that a long exposure to telomerase and telomere inhibitors is necessary to induce anticancer effects. In this paper, we review the most recent information concerning the regulation of telomere length and telomerase expression, with emphasis on mechanisms that might translate into new drug discovery.

Original languageEnglish (US)
Pages (from-to)123-137
Number of pages15
JournalInvestigational New Drugs
Volume18
Issue number2
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

G-Quadruplexes
Telomerase
Telomere
Enzymes
Pharmaceutical Preparations
Proteins
Drug Delivery Systems
Neoplasms
Tankyrases
Telomere-Binding Proteins
Cell Aging
Drug Discovery
Tumor Biomarkers

Keywords

  • Anthraquinone
  • Anticancer drug
  • Drug development
  • Porphyrin
  • Tankyrase
  • Telomerase
  • Telomere
  • TRF1
  • TRF2

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. / Raymond, Eric; Soria, Jean Charles; Izbicka, Elzbieta; Boussin, Francois; Hurley, Laurence; Von Hoff, Daniel D.

In: Investigational New Drugs, Vol. 18, No. 2, 2000, p. 123-137.

Research output: Contribution to journalArticle

Raymond, Eric ; Soria, Jean Charles ; Izbicka, Elzbieta ; Boussin, Francois ; Hurley, Laurence ; Von Hoff, Daniel D. / DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs. In: Investigational New Drugs. 2000 ; Vol. 18, No. 2. pp. 123-137.
@article{ba62a8b6afbf438a8a656f9d4d309da8,
title = "DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs",
abstract = "Telomeres and telomerase have been subjects to a tremendous attention from scientists and oncologists during the past 5 years. This interest has been motivated by the potential of telomerase as a tumor marker for the diagnosis and the prognosis of cancer. The possible use of telomerase or telomeres as new targets for anticancer drugs also triggered investigations. The expression of telomerase was found in overall 85{\%} of cancers. Telomerase is early expressed during oncogenesis with a gradient indicating that a high level of telomerase expression could be associated with a bad prognosis. Therefore, drugs targeting telomerase and telomeres might be useful in many human tumors with little restrictions regarding the tumor type or on the stage of the disease. Moreover, since telomerase is not or slightly expressed in normal cells, it has been postulated that drugs targeting telomerase would induce low toxicity. The race for the discovery of telomerase inhibitors has started while the identification of the components controlling telomerase, telomeres, cell survival, senescence, and apoptosis was still in progress. The recent identification of components regulating telomere length and telomerase expression (TRF1, TRF2, and tankyrase) opened a variety of new opportunities to control telomerase/telomere interactions. Meanwhile, a proof of principle was provided that changing telomere interactions with telomere binding proteins by chemical or biological means can induce cancer cell death. Interestingly, recent data challenge the old paradigm which suggested that a long exposure to telomerase and telomere inhibitors is necessary to induce anticancer effects. In this paper, we review the most recent information concerning the regulation of telomere length and telomerase expression, with emphasis on mechanisms that might translate into new drug discovery.",
keywords = "Anthraquinone, Anticancer drug, Drug development, Porphyrin, Tankyrase, Telomerase, Telomere, TRF1, TRF2",
author = "Eric Raymond and Soria, {Jean Charles} and Elzbieta Izbicka and Francois Boussin and Laurence Hurley and {Von Hoff}, {Daniel D.}",
year = "2000",
doi = "10.1023/A:1006373812586",
language = "English (US)",
volume = "18",
pages = "123--137",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - DNA G-quadruplexes, telomere-specific proteins and telomere-associated enzymes as potential targets for new anticancer drugs

AU - Raymond, Eric

AU - Soria, Jean Charles

AU - Izbicka, Elzbieta

AU - Boussin, Francois

AU - Hurley, Laurence

AU - Von Hoff, Daniel D.

PY - 2000

Y1 - 2000

N2 - Telomeres and telomerase have been subjects to a tremendous attention from scientists and oncologists during the past 5 years. This interest has been motivated by the potential of telomerase as a tumor marker for the diagnosis and the prognosis of cancer. The possible use of telomerase or telomeres as new targets for anticancer drugs also triggered investigations. The expression of telomerase was found in overall 85% of cancers. Telomerase is early expressed during oncogenesis with a gradient indicating that a high level of telomerase expression could be associated with a bad prognosis. Therefore, drugs targeting telomerase and telomeres might be useful in many human tumors with little restrictions regarding the tumor type or on the stage of the disease. Moreover, since telomerase is not or slightly expressed in normal cells, it has been postulated that drugs targeting telomerase would induce low toxicity. The race for the discovery of telomerase inhibitors has started while the identification of the components controlling telomerase, telomeres, cell survival, senescence, and apoptosis was still in progress. The recent identification of components regulating telomere length and telomerase expression (TRF1, TRF2, and tankyrase) opened a variety of new opportunities to control telomerase/telomere interactions. Meanwhile, a proof of principle was provided that changing telomere interactions with telomere binding proteins by chemical or biological means can induce cancer cell death. Interestingly, recent data challenge the old paradigm which suggested that a long exposure to telomerase and telomere inhibitors is necessary to induce anticancer effects. In this paper, we review the most recent information concerning the regulation of telomere length and telomerase expression, with emphasis on mechanisms that might translate into new drug discovery.

AB - Telomeres and telomerase have been subjects to a tremendous attention from scientists and oncologists during the past 5 years. This interest has been motivated by the potential of telomerase as a tumor marker for the diagnosis and the prognosis of cancer. The possible use of telomerase or telomeres as new targets for anticancer drugs also triggered investigations. The expression of telomerase was found in overall 85% of cancers. Telomerase is early expressed during oncogenesis with a gradient indicating that a high level of telomerase expression could be associated with a bad prognosis. Therefore, drugs targeting telomerase and telomeres might be useful in many human tumors with little restrictions regarding the tumor type or on the stage of the disease. Moreover, since telomerase is not or slightly expressed in normal cells, it has been postulated that drugs targeting telomerase would induce low toxicity. The race for the discovery of telomerase inhibitors has started while the identification of the components controlling telomerase, telomeres, cell survival, senescence, and apoptosis was still in progress. The recent identification of components regulating telomere length and telomerase expression (TRF1, TRF2, and tankyrase) opened a variety of new opportunities to control telomerase/telomere interactions. Meanwhile, a proof of principle was provided that changing telomere interactions with telomere binding proteins by chemical or biological means can induce cancer cell death. Interestingly, recent data challenge the old paradigm which suggested that a long exposure to telomerase and telomere inhibitors is necessary to induce anticancer effects. In this paper, we review the most recent information concerning the regulation of telomere length and telomerase expression, with emphasis on mechanisms that might translate into new drug discovery.

KW - Anthraquinone

KW - Anticancer drug

KW - Drug development

KW - Porphyrin

KW - Tankyrase

KW - Telomerase

KW - Telomere

KW - TRF1

KW - TRF2

UR - http://www.scopus.com/inward/record.url?scp=0034065866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034065866&partnerID=8YFLogxK

U2 - 10.1023/A:1006373812586

DO - 10.1023/A:1006373812586

M3 - Article

VL - 18

SP - 123

EP - 137

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -